Analysts’ Updated EPS Estimates for September, 1st (ASHTY, BNED, CIB, COL, CTLT, DANOY, HIIQ, LULU, TECD, UTX)
Ashtead Group (NASDAQ:ASHTY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ashtead Group Plc is an equipment company which provides rental solutions primarily in United States and United Kingdom. The company’s operating segments consists of Sunbelt Rentals and A-Plant. Sunbelt Rentals provides pump and power, climate control and scaffolding services. A-Plant business operates through Eve Trakway Limited, which constructs temporary roadways and barriers; PSS, which offers trenchless technology and fusion services and FLG services. Ashtead Group Plc is headquartered in London, the United Kingdom. “
Barnes & Noble Education (NYSE:BNED) had its buy rating reissued by analysts at BWS Financial. The firm currently has a $14.00 price target on the stock.
BanColombia (NYSE:CIB) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $51.00 target price on the stock. According to Zacks, “BanColombia is Colombia’s largest bank in terms of assets and also has the largest market participation in deposit products and loans. “
Rockwell Collins (NYSE:COL) had its neutral rating reaffirmed by analysts at Credit Suisse Group.
Catalent (NASDAQ:CTLT) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Danone (OTCMKTS:DANOY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Danone SA is engaged in food processing activities primarily in France and internationally. The Company operates in four business lines: Fresh Dairy Products, Waters, Baby Nutrition, and Medical Nutrition. The Fresh Dairy Products division produces and markets yogurts, fermented fresh dairy products, and other specialized fresh dairy products .The Waters division produces and distributes packaged natural, flavored, and vitamin-enriched water. The Baby Nutrition division provides food for infants and toddlers to complement breast-feeding. The Medical Nutrition division offers products to treat disease-related to malnutrition. Danone SA, formerly known as Groupe Danone, is based in Paris, France. “
Health Insurance Innovations (NASDAQ:HIIQ) had its buy rating reissued by analysts at Canaccord Genuity. They currently have a $39.00 price target on the stock.
lululemon athletica inc. (NASDAQ:LULU) had its neutral rating reiterated by analysts at Buckingham Research. Buckingham Research currently has a $55.00 target price on the stock.
lululemon athletica inc. (NASDAQ:LULU) had its hold rating reiterated by analysts at Deutsche Bank AG. Deutsche Bank AG currently has a $59.00 target price on the stock.
Tech Data Corporation (NASDAQ:TECD) had its buy rating reaffirmed by analysts at Loop Capital. The firm currently has a $120.00 target price on the stock, down from their previous target price of $130.00.
United Technologies Corporation (NYSE:UTX) had its neutral rating reiterated by analysts at Credit Suisse Group.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.